Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 4;12(3):326-332.
doi: 10.1093/ckj/sfy122. eCollection 2019 Jun.

Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial

Bancha Satirapoj  1 , Pattharamon Korkiatpitak  1 , Ouppatham Supasyndh  1
Affiliations

Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial

Bancha Satirapoj et al. Clin Kidney J. .

Abstract

Background: Intensive glucose control reduces the risk for microvascular complications in type 2 diabetes (T2DM). Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to exert renoprotection beyond glycemic control, although their effects on the organs are not well known. There are limited data on SGLT2 inhibitors for the biomarkers of kidney injury in type 2 diabetes mellitus (T2DM) patients.

Objective: Our objective was to demonstrate the effect of SGLT2 inhibitors on proximal tubular injury and function in patients with T2DM.

Methods: T2DM patients with persistent glycated hemoglobin (HbA1c) levels >7% were randomly assigned to either dapagliflozin 10 mg/day (n = 28) or standard treatment (n = 29) for 12 weeks. Proximal tubular injury biomarkers, including urine kidney injury molecule-1:creatinine ratio (UKIM1CR), urine cystatin C:creatinine ratio (UCCR), urine albumin:creatinine ratio (UACR), fractional excretion of phosphate (FEPO4) and fractional excretion of uric acid (FEUA) were measured at baseline and study end.

Results: Baseline characteristics were comparable between treatment groups. After 12 weeks, dapagliflozin-treated versus standard-treated patients showed reductions in HbA1c (-0.75 ± 0.21 versus -0.70 ± 0.25%; P = 0.882). There were significant between-group differences in the reduction in UACR {-23.3 [95% confidence interval (CI) -44.4 to -2.2] versus +19.9 (-4.0-43.8) mg/g Cr; P = 0.010} and UKIM1CR [-26.7 (95% CI -232.9-179.5) versus +422.2 (46.7-797.7) ng/g Cr; P = 0.047], but no significant difference in changes in UCCR between the two groups. There was no significant change in glomerular filtration rate, serum phosphate level, FEUA and FEPO4 in the dapagliflozin group. No serious renal-related adverse events were observed in either group.

Conclusions: This study indicates that dapagliflozin in T2DM patients can decrease the levels of urinary proximal tubular injury biomarkers, thus highlighting its renoprotective effect. SGLT2 inhibitors could prove useful in treating T2DM by protecting against renal tubular injury and may lead to reduced long-term renal outcomes.

Keywords: cystatin C; dapagliflozin; kidney injury molecule-1; sodium-glucose cotransporter 2 inhibitor; type 2 diabetes.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Flowchart of the study.
FIGURE 2.
FIGURE 2.
Mean and percentage changes in UACR and UKIM1CR after 12 weeks of treatment. There were no significant changes in mean UACR and UKIM1CR from baseline in both control and dapagliflozin treatment groups, but significantly increased UKIM1CR in the control treatment group. There were significant between-group differences in the mean changes in (A) UACR and (B) KIM1CR (P < 0.05). There was (C) a significant between-group difference in the percentage changes of UACR (P = 0.036) but (D) no significant between-group difference in the percentage changes of UKIM1CR (P = 0.128).
See this image and copyright information in PMC

References

    1. Goff DC Jr, Gerstein HC, Ginsberg HN. et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i–20i - PubMed
    1. Ingsathit A., Thakkinstian A, Chaiprasert P. et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010; 25: 1567–1575 - PubMed
    1. Satirapoj B, Supasyndh O, Mayteedol N. et al. Metabolic syndrome and its relation to chronic kidney disease in a Southeast Asian population. Southeast Asian J Trop Med Public Health 2011; 42: 176–183 - PubMed
    1. Satirapoj B, Adler SG.. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract 2014; 33: 121–131 - PMC - PubMed
    1. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai 2010; 93(Suppl 6): S228–S241 - PubMed